Repeated infusions of VWF/FVIII concentrate: Impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model

Haemophilia

Volumn 17, Issue 5, 2011, Pages 808-814

  Raquet, E ^a   Stockschlader M ^a   Dickneite, G ^a  

^a CSL BEHRING GMBH   (Germany)

Author keywords

Factor VIII; Haemate P; Pharmacokinetics; Trough concentration; Von Willebrand factor; Wilate

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; WILATE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; AREA UNDER CURVE; COAGULANTS; DRUG COMBINATIONS; FACTOR VIII; FEMALE; HALF-LIFE; INFUSIONS, INTRAVENOUS; MODELS, ANIMAL; RABBITS; VON WILLEBRAND FACTOR;

EID: 80052035702     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02603.x     Document Type: Article

References (31)

1. Federici AB, Castaman G, Mannucci PM. Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002; 8: 607-21.
2. Pasi KJ, Collins PW, Keeling DM et al. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10: 218-31.
3. Nichols WL, Hultin MB, James AH et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171-232.
4. Terraube V, O'Donnell JS, Jenkins PV. Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance. Haemophilia 2010; 16: 3-13.
5. Tuddenham EG, Lane RS, Rotblat F et al. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. Br J Haematol 1982; 52: 259-67.
6. Mannucci PM, Chediak J, Hanna W et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002; 99: 450-6.
7. Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med 2004; 351: 683-94.
8. ® P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost 2007; 5: 1420-30.
9. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5.
10. Kyrle PA, Minar E, Hirschl M et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343: 457-62.
11. Bank I, Libourel EJ, Middeldorp S et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 2005; 3: 79-84.
12. Makris M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost 2002; 88: 387-8.
13. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002; 88: 378-9.
14. Girolami A, Tezza F, Scapin M, Vettore S, Casonato A. Arterial and venous thrombosis in patients with von Willebrand's disease: a critical review of the literature. J Thromb Thrombolysis 2006; 21: 175-8.
15. Franchini M. Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage. Blood Transfus 2008; 6(Suppl 2): s33-8.
16. Lethagen S, Carlson M, Hillarp A. A comparative in vitro evaluation of six von Willebrand factor concentrates. Haemophilia 2004; 10: 243-9.
17. ®. Haemophilia 2006; 12(Suppl 2): 18.
18. Budde U, Metzner HJ, Müller HG. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease. Semin Thromb Hemost 2006; 32: 626-35.
19. ® P: history and clinical performance. Eur J Haemato. 2008; 80(Suppl 70): 3-35.
20. ®). Biologicals 2006; 34: 281-8.
21. Gallinaro L, Cattini MG, Sztukowska M et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008; 111: 3540-5.
22. ®) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease. Haematologica 2003; 88: 1279-83.
23. Federici AB, Castaman G, Franchini M et al. Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. Haematologica 2007; 92: 944-51.
24. ® in subjects with inherited von Willebrand disease - are all VWF/FVIII concentrates the same? Haemophilia 2008; 14(Suppl 2): 12.
25. Kessler CM, Powell J, Schwartz BA. Comparison of pharmacokinetic properties of two VWF/FVIII concentrates in subjects with inherited von Willebrand Disease (VWD)-results of a prospective, randomized crossover study. Blood 2010; 116: 3672.
26. Morfini M. The role of FVIII/VWF concentrates in the treatment of von Willebrand disease. Hematol Meeting Rep 2007; 1: 20-6.
27. Dobrkovska A, Krzensk U, Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. Haemophilia 1998; 4(Suppl 3): 33-9.
28. Bello IF, Yuste VJ, Molina MQ, Navarro FH. Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results. Haemophilia 2007; 13(Suppl 5): 25-32.
29. Berntorp E. Haemate P/Humate-P: a systematic review. Thromb Res 2009; 124(Suppl 1): S11-4.
30. Franchini M, Lippi G. The management of patients with congenital von Willebrand disease during surgery or other invasive procedures: focus on antihemophilic factor/von Willebrand factor complex. Biologics 2007; 1: 285-90.
31. Wessler S, Reimer SM, Sheps MC. Biologic assay of a thrombosis-inducing activity in human serum. J Appl Physiol 1959; 14: 943-6.